Dr Sadam Sanwal,Dr Atika Akbar,Dr Muhammad Asif Hussain
Globally allergic rhinitis (AR) has created many health issues and its treatment becomes a challenge. For decades various symptomatic treatments have been available for AR but there has been minor amelioration in the life of a patient and to overcome symptoms burden. In this article we explored the pathophysiological gaps for many AR treatments, explained the pharmacological therapies with their mode of action, Moreover, we considered a newer therapy, MP-AzeFlu consist of an intranasal antihistamine (Azelastine hydrochloride) and Intranasal corticosteroids (futicasone propionate) in a single spray and this combination therapy MP-AzeFlu was found to the best treatment for allergic rhinitis. MP-AzeFlu is simultaneously involved in both phase treatment (first and later phase reaction) in disease and quickly overcome all symptoms of AR. To control the disease in the best way need to discover the prime biomarker and evaluate the disease control parameters.